Infigratinib靶向的FGFR3（成纤维细胞生长因子受体3）正是驱动ACH疾病发生的关键靶点，2月12日，BridgeBio公布Infigratinib在ACH中取得的首个具有统计学显著改善意义的3期顶线结果，公司计划下半年向FDA提交新药申请。
The website you are visiting is protected.
。WPS下载最新地址对此有专业解读
�o�T�FNeoclouds size up enterprise opportunities�iCIO Dive�j��1�FRegulatory risks push cloud leaders to alter infrastructure plans�iCIO Dive�j��2�FNeoclouds helped drive Q3 cloud market surge�iChannel Dive�j��3�F4 tips for evaluating cloud AI providers�iCIO Dive�j��4�FTen Trends That Shaped the Cloud Market in 2024�iIDC�j��5�FThe evolution of neoclouds and their next moves�iMckinsey & Company�j��6�FCoreWeave Expands Agreement with OpenAI by up to $6.�iCoreWeave�j��7�F5 channel trends for 2026�iChannel Dive�j
[&:first-child]:overflow-hidden [&:first-child]:max-h-full"